Hedia ApS EP4681214A1 Patent for Blood Glucose Recommendations
Summary
European Patent Office granted Hedia ApS Patent EP4681214A1 titled 'Computational Architecture to Determine Recommendations for Modifying Patient Blood Glucose Levels' on April 15, 2026. The patent covers methods for determining personalized recommendations for modifying patient blood glucose levels, including insulin dosage calculations. The patent designates 38 European states including all EU member states.
About this source
GovPing monitors EPO Patent Bulletin - Health Informatics (G16H) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 69 changes logged to date.
What changed
EPO granted Hedia ApS Patent EP4681214A1 covering computational methods for determining personalized blood glucose modification recommendations, including insulin dosage calculations based on patient data. The patent was published under IPC classifications G16H 20/17, G16H 20/60, G16H 40/67, G16H 50/20, G16H 50/50, and G16H 50/70, all within the health informatics field.\n\nHedia ApS and its competitors in digital health and diabetes management technology should review this patent when developing or licensing blood glucose recommendation systems to assess potential infringement exposure or licensing opportunities. Companies operating in the blood glucose monitoring and insulin delivery software space should conduct freedom-to-operate analyses given this newly published European patent.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPUTATIONAL ARCHITECTURE TO DETERMINE RECOMMENDATIONS FOR MODIFYING PATIENT BLOOD GLUCOSE LEVELS
Publication EP4681214A1 Kind: A1 Apr 15, 2026
Applicants
Hedia ApS
Inventors
JAKOBSEN, Mads Obdrup, HANSEN, Jonas Meinertz, KARAGKOUNIS, Gkikas, KNUDSEN, Astrid Karnøe, JØRGENSEN, Anders Patrick
IPC Classifications
G16H 20/17 20180101AFI20240927BHEP G16H 20/60 20180101ALI20240927BHEP G16H 40/67 20180101ALI20240927BHEP G16H 50/20 20180101ALI20240927BHEP G16H 50/50 20180101ALI20240927BHEP G16H 50/70 20180101ALI20240927BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Health Informatics (G16H)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Health Informatics (G16H) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.